Evoke Pharma and QOL Medical Conclude Tender Offer Successfully

Evoke Pharma and QOL Medical Announce Expiration of Tender Offer

In a notable event in the biopharmaceutical industry, Evoke Pharma, Inc. (formerly traded as NASDAQ: EVOK) and QOL Medical, LLC have declared the expiration of their tender offer designed to acquire all outstanding shares of Evoke Pharma. This strategic move came to fruition on December 15, 2025, when the offer was officially closed.

Details of the Offer

Evoke stockholders were presented with an enticing offer of $11.00 per share in cash. According to reports from Broadridge Corporate Issuer Solutions, the depositary for the offer, approximately 1,164,862 shares were tendered prior to the expiration, amounting to around 67.63% of Evoke's outstanding shares. This overwhelming response signifies strong support from shareholders for the transaction.

Following the completion of the tender offer, the merger between QOL-EOS Merger Sub, Inc., a wholly-owned subsidiary of QOL Medical, and Evoke Pharma was executed seamlessly. Consequently, all shares not tendered during the offer have been canceled and converted to the right of shareholders to receive the aforementioned offer price, pending appraisal rights exercise. As per the regulations, Evoke Pharma will be delisted from the NASDAQ exchange, concluding its status as a publicly traded entity.

Background on Evoke Pharma

Evoke Pharma is recognized for its specialized focus on developing pharmaceutical solutions for gastrointestinal (GI) disorders, particularly diabetic gastroparesis. Their flagship product, GIMOTI, is a nasal spray formulation of metoclopramide designed to alleviate symptoms associated with this debilitating condition. Given that diabetic gastroparesis affects a significant number of patients globally, GIMOTI addresses a critical need within the pharmaceutical market.

About QOL Medical

Founded in 2003, QOL Medical is a specialty biopharmaceutical company that dedicates itself to finding solutions for rare diseases through the acquisition and commercialization of niche medical products. Its commitment to improving clinical outcomes for patients with rare conditions sets it apart in the competitive biopharmaceutical landscape.

Future Steps for Evoke and QOL Medical

Following the merger, Evoke Pharma is poised to operate as a wholly-owned subsidiary of QOL Medical. The integration of their operations is expected to enhance QOL Medical's portfolio, allowing for a strengthened approach towards addressing rare and underserved medical conditions. This acquisition marks a strategic enlargement for QOL Medical, reflecting its growth ambitions within the biopharmaceutical sector.

Conclusion

The conclusion of this tender offer represents a significant shift for both companies. With the official merging of Evoke Pharma into QOL Medical, stakeholders, including investors and patients alike, can anticipate advancements in therapies for rare gastrointestinal diseases. As the market watches closely, it will be interesting to observe QOL Medical's next moves and how they leverage Evoke's innovative products in pursuit of their mission to transform treatment options for underserved diseases.

In conclusion, the expiration of the tender offer is not just a significant milestone for both Evoke and QOL Medical, but it also signifies the ongoing evolution of the biopharmaceutical landscape, particularly as companies continue to navigate the complexities of acquiring specialized firms to expand their therapeutic reach. The merger serves as a reminder of the importance of patient-centric solutions in the ever-evolving world of medicine.